Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, reported a net loss of $28.8 million for the first quarter of 2025, compared to a net loss of $14.9 million in the same period of 2024. The company holds cash, cash equivalents, and marketable securities totaling $197.9 million as of March 31, 2025, which is expected to support its clinical and operational activities into early 2027. In significant business developments, Acumen has fully enrolled its ALTITUDE-AD Phase 2 study, which investigates the efficacy, safety, and tolerability of sabirnetug for treating early Alzheimer's disease. The study includes 542 participants, and the company anticipates reporting topline results in late 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。